Device Trial Radar · NCT06044974
Nd-YAG Laser Versus Epidermal Growth Factor For Myogenic Tempromandibular Disorder.
Last checked: Nov 19, 2026Latest source record: Aug 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Jan 21, 2023
Primary completion
Aug 10, 2023
Study completion Jan 10, 2024
Sponsor
- Lead sponsor
- Alexandria UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A clinical trial comparing the potential effect of 2 different modalities (Nd-YAG Laser Versus Epidermal growth factor injection) on pain reduction in patients suffering from myogenic tempromandibular disorder.
Conditions
- Temporomandibular Joint Disorders
Interventions
Nd-YAG FotonaDevice
four combined therapy sessions using 1064 nm Nd-YAG laser (once/week)
Epidermal Growth FactorDrug
Epidermal growth factor "EGF-genesis" by Dermaquel Paris n into masseter and temporalis muscles. Each muscle will be divided into 3 zones; origin, body and insertion for masseter muscle, anterior, middle, and posterior for temporalis muscle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain Score (Numerical Rating Scale)Time frame: Pain will be measured at baseline, 7,14,21 days, and 4, 12 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alexandria University
Alexandria, Alexandria Governorate, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.